{
  "docId": "019de074-4969-72b8-bf99-262b9202adeb",
  "docSlug": "32d16c961ba3228c7796678a3b67d91c",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 33,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a vertical process flow to demonstrate the de-risking of the drug candidate.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-4969-72b8-bf99-262b9202adeb/10",
  "deckHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb",
  "deckJsonHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json",
  "deckAnchorHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.45,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Development stages from In Vitro to Phase 2a, CIAS",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9138c90-3cfe-4f9a-9637-36c926127c73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.2,
        "x": 0.75,
        "y": 0.2
      },
      "kind": "list",
      "text": "Consistent PK-PD relationship\nConfidence in active dose range\nComplete CMC package\nExcellent tolerability and safety\nMultiple clinical cognitive signals\nDe-risked path forward",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ddb5580-d8f3-4bcb-965a-c8d4e21ccc40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "1. Pharma developed product in-licensed with extensive pre-clinical & clinical data package\n2. Human Phase 1 + 2 data show replicated, clinically significant learning and memory effects\n3. Well tolerated (>500 subjects dosed)\n4. Initial indication: CIAS",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8a9f531-82ff-49e8-bad9-57e021864127",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Note: CSF = Cerebrospinal Fluid, DPNP = Diabetic Peripheral Neuropathic Pain, PK = Pharmacokinetics, PD = Pharmacodynamics, CNS = Central Nervous System, CMC = Chemistry, Manufacturing, and Controls",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2bc1091-ff73-4e13-b5ad-21f9eb3f7e1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "RL-007: a de-risked pro-cognitive neuromodulator investigated in >500 subjects with excellent tolerability in humans",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0d9c21d-948c-4478-be72-8ce0f3c8c548",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "b8e62650-0693-4b4d-9aef-8a21642a3cc3",
      "evidence": "Vertical flow of clinical development stages",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 10,
      "beatId": "9da964e2-70a1-4fde-828c-8254f9947c58",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The presentation showcases traction for RL-007, including its pro-cognitive effects in human clinical studies (p9) and its Phase 2b trial design (p12).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 33,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae",
      "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.",
      "position": 1,
      "objective": "Why is atai Life Sciences' solution important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}